[{"id":"11021f81-a3eb-4f13-8829-d8eb197afe35","acronym":"S1709-101-888","url":"https://clinicaltrials.gov/study/NCT03594396","created_at":"2021-01-18T17:40:25.695Z","updated_at":"2025-02-25T15:07:45.855Z","phase":"Phase 1/2","brief_title":"Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer","source_id_and_acronym":"NCT03594396 - S1709-101-888","lead_sponsor":"Seoul National University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER-L","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-06-22"}]